• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, August 24, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Holonyak lab team creates fast, cheap, accessible COVID-19 antibody test

Bioengineer by Bioengineer
February 1, 2021
in Health
Reading Time: 3 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: The Grainger College of Engineering

As the numbers of those infected with COVID-19 has continued to climb, the desperate need for a vaccine was apparent. Even now with the invention and administration of several COVID-19 vaccinations, the question remains: How effective are these vaccines? HMNTL students Congnyu Che, Weijing Wang, and Nantao Li, also members of the ECE Nanosensors Group, along with Postdoctoral Researcher Bin Zhao and Professor Brian Cunningham have recently been published in Talanta journal for the development of a cost efficient COVID-19 antibody test.

“Compared with other detection methods, our method is a simple, 15-minute sample-to-answer test,” says Zhao, a postdoctoral research associate and IGB Fellow. “It costs less than $2 per test and is used with a desktop detection system that is suitable for point-of-care situations like clinics and physician offices.”

When COVID-19 began developing into a global crisis in early 2020, this research group was already working on an NIH-funded project to develop a “flu chip” that would rapidly determine the most likely cause of a fever by measuring several proteins within a droplet of blood. They decided to pivot their efforts to detect COVID-19 antibodies instead.

“We made an important breakthrough at the end of May and our method started working,” says Congnyu Che, a BioE and Holonyak Lab graduate student. “After that, it took only a couple of months for us to complete all the experiments that measured detection limits, selectivity against other proteins, and the minimum time needed to get a result.”

Serological (detected by blood sample) antibody testing is an important diagnostic tool for combating the COVID-19 pandemic. Studies have shown that measurement of SARS-CoV-2 specific antibodies may be helpful for the diagnosis of suspected patients with negative RT-PCR results and for the identification of asymptomatic infections – a cause for concern as vaccinations may lessen or eliminate symptoms as well as prevent infection. Quantitative measurement of COVID-19 antibody titer is also vital for blood transfusion therapy, which has shown promising results for treating patients with severe symptoms.

“Quantitative assessment of COVID-19 antibody titer is especially important as clinicians and researchers more fully understand the patient-to-patient variability of immune response, in terms of the onset time for post-infection antibody production, and the post-recovery time that antibodies continue to be present,” says Weijing Wang, a BioE and Holonyak Lab graduate student. “As vaccines become available, it will be urgent for patients to know the extent to which their immune response has been stimulated.”

This highly sensitive, fast, and low-cost test demonstrates great potential for wide applications in diverse working environments. COVID antibody testing could become routine and simple as a variety of vaccines are deployed whose long-term protection is not yet fully known. The test is simple enough to be performed at schools, health clinics, pharmacies, and parts of the world where diagnostic laboratories are not available.

“Our developed method is not only rapid and simple, but also highly sensitive and quantitative. It also requires only a fingerstick quantity of blood (~ 4 μL),” says Nantao Li, an ECE and Holonyak Lab graduate student. “The method that we used to detect COVID-19 antibody can also be adapted to detect other molecules, such as antibodies to other viral pathogens, biomarkers for cardiac disease, and biomarkers for cancer.”

Members of the research group say that, as researchers in the field of disease diagnostics, their mission is to develop innovative analytical methods and tools to provide potentially effective solutions for global public health. They are eager to contribute their expertise to combat the COVID-19 pandemic.

“We are very glad we did it,” says Zhao. “Without any one of us, this group couldn’t have finished the work so quickly and efficiently. We all put forward many great ideas and were all very active during the experimental process.”

The team says they also want to encourage everyone to continue social distancing and mask wearing even as vaccines are distributed.

###

Media Contact
Lizzie Roehrs
[email protected]

Original Source

https://mntl.illinois.edu/news/30352

Related Journal Article

http://dx.doi.org/10.1016/j.talanta.2020.122004

Tags: BiotechnologyMedicine/HealthTechnology/Engineering/Computer Science
Share12Tweet8Share2ShareShareShare2

Related Posts

Study reveals surge in type 2 diabetes among people under 20

August 24, 2026

Blocking glucosylceramide production kills cancer cells via lysosomal dysfunction, not ceramide buildup

August 23, 2026

ZCCHC4 boosts replication-dependent histone mRNA translation by interacting with eIF3

August 23, 2026

Tirzepatide Versus GLP-1 Agonists for Stroke Risk in Atrial Fibrillation and Diabetes

August 22, 2026
Please login to join discussion

POPULAR NEWS

  • Cochrane Map Reveals Major Evidence Gaps in Dengue Prevention Research

    Cochrane Map Reveals Major Evidence Gaps in Dengue Prevention Research

    29 shares
    Share 12 Tweet 7
  • Study reveals surge in type 2 diabetes among people under 20

    29 shares
    Share 12 Tweet 7
  • KAIST discovers pathway to faster-charging, longer-lasting electric vehicle batteries

    29 shares
    Share 12 Tweet 7
  • Blocking glucosylceramide production kills cancer cells via lysosomal dysfunction, not ceramide buildup

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Cochrane Map Reveals Major Evidence Gaps in Dengue Prevention Research

Study reveals surge in type 2 diabetes among people under 20

KAIST discovers pathway to faster-charging, longer-lasting electric vehicle batteries

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 85 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.